In light of the multiple pathways that may be responsible for the onset of AD, developing therapies are designed to focus on a variety of targets that include DNA methylation, deployment of monoclonal antibodies against Aβ, prevention of Aβ and tau aggregation, increased cytokine and growth factor signal transduction, mammalian target of rapamycin (mTOR) modulation, and the application of metal chelators [14, 15, 17, 18, 21–27]. Here, MTOR is linked to Alzheimer disease.